Loading
Latest filing published 11 Oct 2011 for MARIZYME, INC., €4,740.
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Mark William Durst on record concern Marizyme, Inc. In total, 5 filings cover trades dated from 12 September 2011 to 11 October 2011.
In open-market terms, that means 2 purchases worth €16k on one side and 3 sales worth €20k on the other. Sales outweigh purchases by €3,865. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
Most recently, on 13 October 2011, the filings show an open-market purchase worth €12k in Marizyme, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations